Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
CEO and CFO of Veracyte sold shares amid strong earnings and positive stock performance.
On December 4, 2025, Veracyte CEO Marc Stapley sold 7,668 shares at $47.09 each, reducing his stake by 2.35%, while CFO Rebecca Chambers sold 13,278 shares at $46.84, cutting her holding by 10.81%.
Both transactions were filed with the SEC.
The company reported strong third-quarter earnings on November 4, with $0.51 EPS and $131.87 million in revenue, up 13.8% year-over-year.
Veracyte’s stock closed at $47.41 on December 4, down $0.34, with a market cap of $3.75 billion and a consensus “Moderate Buy” rating.
5 Articles
CEO y CFO de Veracyte vendieron acciones en medio de fuertes ganancias y un desempeño positivo de las acciones.